In this study, to avoid an overwhelming GVHD, CsA was withdrawn by 10%/week in patients without aGVHD by day +30, and granulocyte colony-stimulating factor (G-CSF)-mobilized DLI was administrated in patients without grade II/>II aGVHD by day +60 or in those without GVHD but MRD positive by day +90. This evidence concerns the gene CSF3 and graft versus host disease.